Femasys today announced it received FDA 510(k) clearance for its FemChec contrast-generating device that checks fallopian tubal status. Atlanta-based Femasys designed FemChec for controlled delivery of contrast to confirm tubal status. It alternates between a pattern of saline and air in a continuous stream of contrast media. “FemChec is an essential part of our suite […]
Femasys
Femasys secures nearly $7M in funding from PharmaCyte
Femasys this week announced it received a strategic upfront investment of $6.85 million from biotech company PharmaCyte Biotech. Atlanta-based Femasys is developing a broad portfolio of in-office and accessible therapeutic and diagnostic products for women worldwide. Its FemBloc is in late-stage clinical development for permanent birth control. Its FemSeed for infertility treatment is FDA-cleared and […]
